Gut microbiota composition during hospitalization is associated with 60-day mortality after severe COVID-19.
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
23 02 2023
23 02 2023
Historique:
received:
20
12
2022
accepted:
12
02
2023
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
25
2
2023
Statut:
epublish
Résumé
Gut microbiota alterations have been reported in hospitalized COVID-19 patients, with reduced alpha diversity and altered microbiota composition related to respiratory failure. However, data regarding gut microbiota and mortality are scarce. Rectal swabs for gut microbiota analyses were collected within 48 h after hospital admission (baseline; n = 123) and three-month post-admission (n = 50) in a subset of patients included in the Norwegian SARS-CoV2 cohort study. Samples were analysed by sequencing the 16S rRNA gene. Gut microbiota diversity and composition at baseline were assessed in relation to need for intensive care unit (ICU) admission during hospitalization. The primary objective was to investigate whether the ICU-related gut microbiota was associated with 60-day mortality. Gut microbiota diversity (Shannon index) at baseline was lower in COVID-19 patients requiring ICU admission during hospitalization than in those managed in general wards. A dysbiosis index representing a balance of enriched and reduced taxa in ICU compared with ward patients, including decreased abundance of butyrate-producing microbes and enrichment of a partly oral bacterial flora, was associated with need of ICU admission independent of antibiotic use, dexamethasone use, chronic pulmonary disease, PO Although our data should be regarded as exploratory due to low number of clinical end points, they suggest that gut microbiota alterations during hospitalization could be related to poor prognosis after severe COVID-19. Larger studies of gut involvement during COVID-19 in relation to long-term clinical outcome are warranted. Trial registration NCT04381819 . Retrospectively registered May 11, 2020.
Sections du résumé
BACKGROUND
Gut microbiota alterations have been reported in hospitalized COVID-19 patients, with reduced alpha diversity and altered microbiota composition related to respiratory failure. However, data regarding gut microbiota and mortality are scarce.
METHODS
Rectal swabs for gut microbiota analyses were collected within 48 h after hospital admission (baseline; n = 123) and three-month post-admission (n = 50) in a subset of patients included in the Norwegian SARS-CoV2 cohort study. Samples were analysed by sequencing the 16S rRNA gene. Gut microbiota diversity and composition at baseline were assessed in relation to need for intensive care unit (ICU) admission during hospitalization. The primary objective was to investigate whether the ICU-related gut microbiota was associated with 60-day mortality.
RESULTS
Gut microbiota diversity (Shannon index) at baseline was lower in COVID-19 patients requiring ICU admission during hospitalization than in those managed in general wards. A dysbiosis index representing a balance of enriched and reduced taxa in ICU compared with ward patients, including decreased abundance of butyrate-producing microbes and enrichment of a partly oral bacterial flora, was associated with need of ICU admission independent of antibiotic use, dexamethasone use, chronic pulmonary disease, PO
CONCLUSIONS
Although our data should be regarded as exploratory due to low number of clinical end points, they suggest that gut microbiota alterations during hospitalization could be related to poor prognosis after severe COVID-19. Larger studies of gut involvement during COVID-19 in relation to long-term clinical outcome are warranted. Trial registration NCT04381819 . Retrospectively registered May 11, 2020.
Identifiants
pubmed: 36814280
doi: 10.1186/s13054-023-04356-2
pii: 10.1186/s13054-023-04356-2
pmc: PMC9946863
doi:
Substances chimiques
RNA, Ribosomal, 16S
0
RNA, Viral
0
Banques de données
ClinicalTrials.gov
['NCT04381819']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
69Informations de copyright
© 2023. The Author(s).
Références
Pathogens. 2022 Sep 15;11(9):
pubmed: 36145482
Med Microecol. 2020 Sep;5:100023
pubmed: 34173452
Crit Care. 2022 Oct 3;26(1):300
pubmed: 36192756
Nat Commun. 2020 Jul 14;11(1):3514
pubmed: 32665548
Sci Immunol. 2020 May 13;5(47):
pubmed: 32404436
Nature. 2022 Mar;603(7902):706-714
pubmed: 35104837
Med (N Y). 2022 Jun 10;3(6):371-387.e9
pubmed: 35434682
J Comput Biol. 2017 Nov;24(11):1138-1143
pubmed: 28715235
Crit Care. 2018 Mar 20;22(1):78
pubmed: 29559006
Lancet Gastroenterol Hepatol. 2020 Jul;5(7):667-678
pubmed: 32405603
JAMA. 2022 Nov 15;328(19):1922-1934
pubmed: 36286098
mSystems. 2018 Jul 17;3(4):
pubmed: 30035234
Sci Transl Med. 2020 Aug 12;12(556):
pubmed: 32801143
Eur Respir J. 2023 Feb 9;61(2):
pubmed: 36229047
Science. 2020 Jul 3;369(6499):50-54
pubmed: 32358202
Nature. 2013 Dec 19;504(7480):446-50
pubmed: 24226770
Nat Biotechnol. 2019 Aug;37(8):852-857
pubmed: 31341288
World J Gastroenterol. 2020 Aug 21;26(31):4579-4588
pubmed: 32884218
PLoS One. 2017 Oct 26;12(10):e0185056
pubmed: 29073143
NPJ Biofilms Microbiomes. 2021 Jul 22;7(1):61
pubmed: 34294722
Gut. 2022 Mar;71(3):544-552
pubmed: 35082169
Nat Rev Gastroenterol Hepatol. 2022 Oct 21;:
pubmed: 36271144
Front Immunol. 2021 Jan 25;11:607734
pubmed: 33569053
Microbiol Spectr. 2021 Oct 31;9(2):e0005521
pubmed: 34643448
JAMA. 2022 Nov 15;328(19):1911-1921
pubmed: 36286097
Nucleic Acids Res. 2013 Jan;41(Database issue):D590-6
pubmed: 23193283
Signal Transduct Target Ther. 2021 May 13;6(1):191
pubmed: 33986253
Front Cell Infect Microbiol. 2021 Jun 29;11:670424
pubmed: 34268136
J Intern Med. 2022 Nov;292(5):816-828
pubmed: 35982589
J Intern Med. 2022 Jun;291(6):801-812
pubmed: 35212063
Microorganisms. 2020 Oct 01;8(10):
pubmed: 33019592
Gastroenterology. 2020 Sep;159(3):944-955.e8
pubmed: 32442562
Gastroenterology. 1994 Jan;106(1):35-41
pubmed: 8276206
Microbiome. 2018 May 17;6(1):90
pubmed: 29773078
Front Med (Lausanne). 2022 Feb 14;9:821777
pubmed: 35237631
Clin Infect Dis. 2020 Dec 17;71(10):2669-2678
pubmed: 32497191